LexDanaLexDanabeta
Inventor

Nigel J. Liverton

Inventor
Harleysville, PA, US

Overview

82→
Patents
1995–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 82 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds35%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%
A61KPreparations for medical, dental or toiletry purposes16%
C07KPeptides8%
Y02ATechnologies for adaptation to climate change2%
C07CAcyclic or carbocyclic compounds1%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
C07BGeneral methods of organic chemistry1%
A23KFodder0%
A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for0%
PatentTitleYear
10,961,215N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use202110,894,775Piperidine derivatives as liver X receptor beta agonists, compositions, and their use202110,435,398Oxazole orexin receptor antagonists201910,308,645Piperidine oxadiazole and thiadiazole orexin receptor antagonists201910,239,838Heteroaryl orexin receptor antagonists201910,214,535Hydroxmethyl piperidine orexin receptor antagonists201910,155,750Amidoethyl azole orexin receptor antagonists201810,150,751Pyrrolidine orexin receptor antagonists201810,017,504Piperidine isoxazole and isothiazole orexin receptor antagonists201810,011,595Ethyldiamine orexin receptor antagonists201810,010,539Pyrazole, triazole and tetrazole orexin receptor antagonists20189,987,2555,5-bicyclic oxazole orexin receptor antagonists20189,938,2766,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists20189,920,038'Methyl oxazole orexin receptor antagonists'20189,828,368Oxazole orexin receptor antagonists20179,765,091'Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors'20179,738,661'HCV NS3 protease inhibitors'20179,573,939'Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases'20179,549,917'Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases'20179,328,138'HCV NS3 protease inhibitors'20169,265,773'Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases'20168,927,569'Macrocyclic compounds as antiviral agents'20158,828,930'Hepatitis C virus NS3 protease inhibitors'20148,591,878'Therapeutic compounds'20138,461,107'HCV NS3 protease inhibitors'20138,377,873'HCV NS3 protease inhibitors'20138,377,874'HCV NS3 protease inhibitors'20138,338,449'Isoquinolinone potassium channel inhibitors'20128,309,540'HCV NS3 protease inhibitors'20128,278,322'HCV NS3 protease inhibitors'20128,216,999'HCV NS3 protease inhibitors'20128,138,164'HCV NS3 protease inhibitors'20128,080,654'Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors'20117,973,040'Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors'20117,879,797'HCV NS3 protease inhibitors'20117,763,614'Isoquinoline potassium channel inhibitors'20107,723,352'Isoquinolinone potassium channel inhibitors'20107,592,360'3-fluoro-piperidines as NMDA/NR2B antagonists'20097,470,664'HCV NS3 protease inhibitors'20087,452,893'4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists'20087,259,157'N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists'20077,217,716'N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists'20077,196,095'(Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds'20077,053,089'N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists'20066,870,055'Isoquinolinone potassium channels inhibitors'20056,838,291'Radioligand and binding assay'20056,767,908'Substituted imidazoles having cytokine inhibitory activity'20046,632,836'Carbocyclic potassium channel inhibitors'20036,602,872'Substituted pyridazines having cytokine inhibitory activity'20036,492,516'Compounds having cytokine inhibitory activity'20026,440,976'Iminopyrimidine NMDA NR2B receptor antagonists'20026,403,596'Substituted pyridones having cytokine inhibitory activity'20026,376,530'Cyclic amidines useful as NMDA NR2B antagonists'20026,319,944'Aryl amidines, compositions containing such compounds and methods of use'20016,316,474'2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists'20016,303,637'Heterocyclic potassium channel inhibitors'20016,291,457'Compounds having cytokine inhibitory activity'20016,214,823'Benzodiazepine derivatives as antiarrhythmic agents'20016,207,687'Substituted imidazoles having cytokine inhibitory activity'20016,194,458'Benzamide potassium channel inhibitors'20016,083,949'Substituted imidazoles having anti-cancer and cytokine inhibitory activity'20005,859,041'Substituted imidazoles having cytokine inhibitory activity'19995,837,719'2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use'19985,821,241'Fibrinogen receptor antagonists'19985,792,778'2-substituted aryl pyrroles, compositions containing such compounds and methods of use'19985,726,171'N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo›B!›1,4!diazepi n-3yl)-acetamides'19985,717,100'Substituted imidazoles having anti-cancer and cytokine inhibitory activity'19985,700,797'N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides'19975,696,111'3-acylaminobenzazepines'19975,691,331'N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides'19975,691,332'N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides'19975,679,672'Benzodiazepines'19975,658,901'2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzo diazepines'19975,633,251'N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines'19975,631,251'5-cyclopropyl-1,4 benzodiazepine-2-ones'19975,595,990'Antiarrhythmic benzodiazepines'19975,451,578'Fibrinogen receptor antagonists'19955,441,952'Fibrinogen receptor antagonists'19955,438,055'Antiarrhythmic benzodiazepines'19955,428,157'3-acylaminobenzodiazepines'19955,426,185'Antiarrhythmic benzodiazepines'19955,389,631'Fibrinogen receptor antagonists'1995

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1995–2009Patents assigned to MERCK & CO INC (45)· patent assignee history
1995–2021Based in Harleysville, PA, US· patent location history
1997Based in Harleyville, PA, US· patent location history
1998Based in West Point, PA, US· patent location history
2010–2021Patents assigned to MERCK SHARP & DOHME (37)· patent assignee history
2011–2021Patents assigned to LIVERTON NIGEL J (16)· patent assignee history
2011–2015Patents assigned to MCCAULEY JOHN A (9)· patent assignee history
2012–2021Patents assigned to RUDD MICHAEL T (9)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
MERCK & CO INC451995–2009
MERCK SHARP & DOHME372010–2021
LIVERTON NIGEL Jself162011–2021
MCCAULEY JOHN A92011–2015
RUDD MICHAEL T92012–2021
Locations
LocationPatentsSpan
Harleysville, Pennsylvania, US801995–2021
West Point, Pennsylvania, US11998
Harleyville, Pennsylvania, US11997